Tivozanib

Drug Profile

Tivozanib

Alternative Names: ASP 4130; AV-951; Kil8951; KRN-951; Tivopath

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; AVEO Oncology; Institute Gustave-Roussy; Kyowa Hakko Kirin
  • Class Antineoplastics; Isoxazoles; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preregistration Renal cell carcinoma
  • Phase I Solid tumours
  • Suspended Breast cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 19 May 2017 EUSA Pharma completes oral explanation to CHMP for tivozanib for Renal cell carcinoma
  • 13 Apr 2017 EUSA Pharma submits responses to Day 180 List of Outstanding Issues from CHMP for tivozanib
  • 31 Mar 2017 Tivozanib is available for licensing for non-oncologic indications in World as of 31 Mar 2017. www.aveooncology.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top